Biotech entity
pharma is the sole category represented across all 3 tracked stories. Eli Lilly is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. They are better corroborated than the beat average, carrying 7.3 original sources each against 4 for the same window.
Last mentioned: Jul 19, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 3 tracked stories. Eli Lilly is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. They are better corroborated than the beat average, carrying 7.3 original sources each against 4 for the same window. Across a 145-day span, the pace is roughly 0.1 stories per week. Their average consequence score of 6.3 runs above the beat's 6.2 for that window. This profile follows 3 Biotech stories mentioning TrumpRx across the period from February 25, 2026 to July 19, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 490 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TrumpRx. Shared-story counts are live from our verified record — not editorial picks.
Operational Launch
New facilities expected to come online to support next-gen drug production.
Construction Start
Anticipated ground-breaking for the two new advanced manufacturing sites.
Manufacturing Expansion
AbbVie announces $380 million investment for North Chicago API facilities.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and capital investments over the next decade.
Biopharma companies cooperated just enough to avoid tariffs, placing only 92 products on TrumpRx while keeping high-margin cancer, HIV, and inflammation therapies off the discount menu—revealing industry’s strategic calculus.
TrumpRx, the Trump administration's drug discount website, has secured voluntary pricing deals on only 92 brand-name drugs—less than 12% of the 800-plus products from 17 major pharmaceutical companies. High-cost therapies for inflammatory diseases, HIV, and cancer are largely excluded, raising doubts about industry's willingness to compromise on pricing without legislation.
AbbVie has announced a $380 million investment to expand its manufacturing capabilities in North Chicago, Illinois, marking the first major step in a decade-long $100 billion commitment to U.S. research and development. The move aligns with federal efforts to localize pharmaceutical supply chains and reduce drug prices through direct-to-patient initiatives like TrumpRx.
TrumpRx is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
